April 16th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pembrolizumab Extends PFS in Newly Diagnosed MSI-H/dMMR mCRC
May 28th 2020"Pembrolizumab works in non-randomized studies in this group of patients with advanced disease. This randomized study demonstrates a huge benefit in the first-line [setting] with pembrolizumab and should be the new standard of care."
Read More
TIL Density and Tumor Budding Validated as Prognostic Factors for DFS in Stage III CRC
May 28th 2020“[The study confirmed] that use of Immunoscore® in combination with established prognostic factors allows one to more accurately assess prognosis, highlighting the clinical utility of Immunoscore."
Read More
Onvansertib Receives FDA Fast Track Designation in KRAS+ mCRC
May 28th 2020"This designation is a significant validation of not only our onvansertib clinical program, which is now eligible for priority review and accelerated approval, but it also signifies recognition of the medical need for new effective treatment options.”
Read More
The Expanding Continuum of Care in Metastatic Colorectal Cancer
May 13th 2020Colorectal cancer is among the most commonly diagnosed malignancies worldwide, representing 10.2% of all cancer cases. The recent addition of third- and fourth-line therapies that extend survival and improve quality of life has opened up new possibilities in the growing continuum of care for metastatic colorectal cancer.
Read More
Implications Arise for Combined Genomic and Epigenomic ctDNA Analysis for CRC Detection
May 4th 2020“This combined genomic and epigenomic plasma-based ctDNA test continues to demonstrate high sensitivity and specificity which significant implications for its clinical utility of CRC detection,”
Read More
Treating Early Onset Colorectal Cancer in Young Adults
April 29th 2020In an interview with Targeted Oncology following SOGO 2020, Andrea Cercek, MD, discussed the rising incidence of CRC in young adults in detail. She also advised community oncologists who encounter these patients in their clinics.
Read More
FDA Approves Novel Diagnostic Assay to Accompany Encorafenib in Treatment of mCRC
April 16th 2020The FDA has granted approval to the therascreen BRAF V600E Kit as a companion diagnostic to encorafenib, a BRAF inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected by an FDA approved test, in combination with cetuximab after prior therapy.<br />
Read More
FDA Approves Encorafenib Plus Cetuximab in BRAF V600E+ mCRC
April 9th 2020The FDA has approved the combination of encorafenib and cetuximab as treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy, according to a press release from Pfizer.
Read More
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 7th 2020The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Read More
Pembrolizumab Meets PFS Milestone for Patients with MSI-H/dMMR mCRC
April 6th 2020Pembrolizumab demonstrated an improvement in progression-free survival in the first-line treatment of patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer, meeting one of the primary end points of the phase III KEYNOTE-177 trial.
Read More
Tweet Chat Recap: Evaluating Treatment Options for Rare Subsets of Colorectal Cancer
April 1st 2020In honor of Colorectal Cancer Awareness Month, <em>Targeted Oncology</em> was joined by Pashtoon M. Kasi, MD, MBBS, MS, in a tweet chat. The 3 featured cases highlighted a variety of subsets of CRC, including patients with NTRK fusions, <em>BRAF</em> mutations, and HER2 amplifications.
Read More
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
March 30th 2020An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
Read More
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care
March 30th 2020A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
Read More
Sequential Genomic Testing Could Reveal Efficacy, Patterns of Resistance in Metastatic CRC
March 28th 2020The use of genetic testing by way of tumor tissue analysis combined with liquid biopsy monitoring at different time points throughout the disease progression of colorectal cancer may help optimize treatment selection.
Read More
Cetuximab Skin Toxicity Has Predictive and Prognostic Correlation With OS in mCRC
March 25th 2020The addition of cetuximab to irinotecan, fluorouracil, and folinic acid leucovorin demonstrated superior overall survival compared with the addition of bevacizumab in patients with metastatic colorectal cancer who developed skin toxicity from cetuximab exposure, according to results from the phase II FIRE-3 trial, published in the Annals of Oncology.
Read More
Cetuximab Plus Chemotherapy Worsens Survival in Resectable Colorectal Liver Metastases
March 24th 2020Despite demonstrating improvement in overall survival as treatment of patients with advanced inoperable metastatic colorectal cancer, cetuximab plus chemotherapy led to significantly worse survival for patients with operable colorectal liver metastases in the perioperative setting, according to findings from randomized phase III clinical trial.
Read More
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic
March 23rd 2020In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />
Read More
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations
March 21st 2020Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Read More
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
March 20th 2020Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
Read More